FIELD: medicine. SUBSTANCE: method involves carrying out biochemical examination of leprosy patient blood serum. The amount of peroxidation-modified heparin-containing apo-B-containing lipoproteins is to be determined. The level of 3.45 mcmole/g of protein being found in the sample, liver disorder is to be diagnosed. EFFECT: high accuracy of diagnosis. 2 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD OF DIAGNOSIS OF LEPROUS PROCESS ACTIVITY | 2000 |
|
RU2170431C1 |
METHOD FOR PREDICTING LEPROUS NODULAR ERYTHEMA PROGRESS | 2000 |
|
RU2171991C1 |
METHOD OF IDENTIFICATION OF MYCOBACTERIUM LEPRAE IN PATIENTS WITH DISEASE REGRESSION | 1997 |
|
RU2137137C1 |
METHOD OF LEPROSY DIAGNOSIS | 1996 |
|
RU2124730C1 |
METHOD FOR DIAGNOSING LEPROSIS | 2000 |
|
RU2171689C1 |
METHOD OF DETECTION OF SPECIFIC LIVER DISEASE IN LEPROSY PATIENTS | 2009 |
|
RU2403869C1 |
METHOD OF ESTIMATION OF LEPROSY RELAPSE RISK GROUP | 1993 |
|
RU2082979C1 |
METHOD FOR DETECTING THE ACTIVITY OF CHRONIC HEPATIC LESION IN PATIENTS WITH MULTIBACTERIAL FORM OF LEPROSY | 2006 |
|
RU2306568C1 |
METHOD FOR DETERMINING LEPROSY FORM | 2004 |
|
RU2279087C2 |
METHOD OF TREATMENT OF CHRONIC NEURITIDES IN PATIENTS ILL WITH LEPRA | 1996 |
|
RU2135152C1 |
Authors
Dates
2002-08-27—Published
2000-04-28—Filed